CAR-T cell therapy for recurrent glioblastoma
Part of Cancer clinical trials.
This trial tests a new CAR-T cell treatment (SNC-109) for people with glioblastoma that has come back after initial treatment. The therapy uses your own immune cells, modified in a lab, to try to attack the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have recurrent glioblastoma (a type of brain tumor that has come back) confirmed by a biopsy or previous treatment.
- You are able to do daily activities with minimal help (score of 50 or more on the Karnofsky scale).
- Your life expectancy is at least 12 weeks.
- You are not pregnant and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a new type of immune cell therapy (CAR-T cells) made from donor cells, designed to target tumors with a specific marker called CD70. It is for people whose brain glioma has come back or hasn't responded to standard treatments.
This trial tests a new type of immunotherapy called CAR-T cells, made from donor cells, for people whose glioblastoma (a type of brain cancer) has come back after standard treatment. The goal is to see if it can shrink the tumor or slow its growth.
This Phase 1 study tests a personalized immune-cell treatment (CAR-T) made from your own cells to attack a marker called B7-H3 on recurring glioblastoma. It may help shrink or control the tumor, but the main goal is to check safety and how the treatment works.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD276 found on glioblastoma cells. It's for people whose glioblastoma has come back or not responded to standard treatments, and who have no other good options left.
This trial tests a new type of CAR T-cell therapy that targets a specific protein (EGFRvIII) found on some glioblastoma cells. The treatment is designed to be more effective and potentially safer for people whose brain tumor has come back after previous treatments.
Hear when a new Recurrent Glioblastoma Multiforme (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.